FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200490482> ?p ?o ?g. }

• W4200490482 abstract "Background: Prostate cancer is one of the most frequently diagnosed solid malignancies and is accountable for the second highest cancer-related deaths in males worldwide. Despite the success of targeting the androgen receptor signaling pathway with androgen deprivation therapy (ADT) and androgen receptor blockage (ARB), relapse and resistance to treatment leads to castration resistant prostate cancer (CRPC) or metastatic CRPC (mCRPC), resulting in poor clinical prognosis and therapeutic outcome. Prostate cancer is a highly heterogeneous disease, with different molecular pathways playing a role in the advanced disease, such as androgen receptor mutations, DNA repair gene deletions, P53 aberrations, RB1 function loss, as well as gene rearrangements, like TMPRSS2-ERG2. Preclinical models representing CRPC heterogeneity and clinically relevant responses to standard of care treatments are needed to better understand the biology and mechanisms of this malignancy. METHODS: CRPC PDX models derived from metastases of prostate cancer patients, which failed anti-androgen therapies, were established via subcutaneous engraftment in immunodeficient mice. Model classification and characterization were performed by histopathology and immunohistochemistry (IHC) with prostate-specific biomarkers. Genomic profiling of these models was performed by next generation sequencing (NGS). Chemotherapies such as docetaxel and target therapies, including anti-androgen, were evaluated in these prostate models. Tumor volume over time was used to determine growth rate and response to treatment in uncastrated and castrated mice. RESULTS: A series of CRPC PDX models derived from metastatic lesions in patients, including metastases from lymph nodes, bladder, ascites and rib/soft bone, were established and characterized. Histopathology by H&E staining presented distinct features of adenocarcinoma and the immunohistochemistry data indicated various expression levels of prostate-specific markers, such as prostate-specific antigen (PSA) and androgen receptor (AR). Most of the models showed loss of PTEN expression. Sequencing data also detected different gene aberrations such as TMPRSS2-ERG fusion, TP53 deletion and mutations, RB1 mutations, and AR alterations. In vivo modeling of these models presented tumor progression under castration. Docetaxel and enzalutamide, commonly used in mCRPC patients, presented varied responses. CONCLUSIONS: Prostate cancer presents high heterogenicity in clinical and molecular features, and treatment response. A panel of mCRPC PDX models have been established and characterized to provide clinically relevant preclinical models for prostate cancer therapeutic evaluation.Citation Format: Jessie Jingjing Wang, Leilei Chen, Xueying Yang, Likun Zhang, Wubin Qian, Henry Qixiang Li. Establishment and characterization of a panel of advanced prostate cancer patient-derived xenograft (PDX) models for cancer therapeutic evaluation [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2021 Oct 7-10. Philadelphia (PA): AACR; Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P005." @default.
• W4200490482 created "2021-12-31" @default.
• W4200490482 creator A5016139817 @default.
• W4200490482 creator A5024674202 @default.
• W4200490482 creator A5049711882 @default.
• W4200490482 creator A5052281306 @default.
• W4200490482 creator A5055342873 @default.
• W4200490482 creator A5087333826 @default.
• W4200490482 date "2021-12-01" @default.
• W4200490482 modified "2023-10-16" @default.
• W4200490482 title "Abstract P005: Establishment and characterization of a panel of advanced prostate cancer patient-derived xenograft (PDX) models for cancer therapeutic evaluation" @default.
• W4200490482 doi "https://doi.org/10.1158/1535-7163.targ-21-p005" @default.
• W4200490482 hasPublicationYear "2021" @default.
• W4200490482 type Work @default.
• W4200490482 citedByCount "0" @default.
• W4200490482 crossrefType "proceedings-article" @default.
• W4200490482 hasAuthorship W4200490482A5016139817 @default.
• W4200490482 hasAuthorship W4200490482A5024674202 @default.
• W4200490482 hasAuthorship W4200490482A5049711882 @default.
• W4200490482 hasAuthorship W4200490482A5052281306 @default.
• W4200490482 hasAuthorship W4200490482A5055342873 @default.
• W4200490482 hasAuthorship W4200490482A5087333826 @default.
• W4200490482 hasConcept C121608353 @default.
• W4200490482 hasConcept C126322002 @default.
• W4200490482 hasConcept C142724271 @default.
• W4200490482 hasConcept C143998085 @default.
• W4200490482 hasConcept C2776235491 @default.
• W4200490482 hasConcept C2777899217 @default.
• W4200490482 hasConcept C2777911890 @default.
• W4200490482 hasConcept C2779013556 @default.
• W4200490482 hasConcept C2779399171 @default.
• W4200490482 hasConcept C2780192828 @default.
• W4200490482 hasConcept C2781190966 @default.
• W4200490482 hasConcept C502942594 @default.
• W4200490482 hasConcept C544855455 @default.
• W4200490482 hasConcept C61367390 @default.
• W4200490482 hasConcept C71315377 @default.
• W4200490482 hasConcept C71924100 @default.
• W4200490482 hasConceptScore W4200490482C121608353 @default.
• W4200490482 hasConceptScore W4200490482C126322002 @default.
• W4200490482 hasConceptScore W4200490482C142724271 @default.
• W4200490482 hasConceptScore W4200490482C143998085 @default.
• W4200490482 hasConceptScore W4200490482C2776235491 @default.
• W4200490482 hasConceptScore W4200490482C2777899217 @default.
• W4200490482 hasConceptScore W4200490482C2777911890 @default.
• W4200490482 hasConceptScore W4200490482C2779013556 @default.
• W4200490482 hasConceptScore W4200490482C2779399171 @default.
• W4200490482 hasConceptScore W4200490482C2780192828 @default.
• W4200490482 hasConceptScore W4200490482C2781190966 @default.
• W4200490482 hasConceptScore W4200490482C502942594 @default.
• W4200490482 hasConceptScore W4200490482C544855455 @default.
• W4200490482 hasConceptScore W4200490482C61367390 @default.
• W4200490482 hasConceptScore W4200490482C71315377 @default.
• W4200490482 hasConceptScore W4200490482C71924100 @default.
• W4200490482 hasLocation W42004904821 @default.
• W4200490482 hasOpenAccess W4200490482 @default.
• W4200490482 hasPrimaryLocation W42004904821 @default.
• W4200490482 hasRelatedWork W2140855177 @default.
• W4200490482 hasRelatedWork W2501991984 @default.
• W4200490482 hasRelatedWork W2770702948 @default.
• W4200490482 hasRelatedWork W3023947295 @default.
• W4200490482 hasRelatedWork W3089863507 @default.
• W4200490482 hasRelatedWork W3200282916 @default.
• W4200490482 hasRelatedWork W4226303148 @default.
• W4200490482 hasRelatedWork W4229076799 @default.
• W4200490482 hasRelatedWork W4295154856 @default.
• W4200490482 hasRelatedWork W4297472852 @default.
• W4200490482 isParatext "false" @default.
• W4200490482 isRetracted "false" @default.
• W4200490482 workType "article" @default.